Gan Li Pharmaceuticals: Clinical trial approval granted for new indication of Bofan Semaglutide Injection

MetaMuskRat · 2026-03-25T19:04:22+00:00

Ganlee Pharmaceutical's wholly-owned subsidiary has received approval from the National Medical Products Administration for Bofan Semaglutide Injection to include a new indication for the treatment of moderate to severe obstructive sleep apnea in adult patients with obesity, and it is currently undergoing Phase III clinical trials.

MetaMuskRat

2026-03-25 19:04:22

Abstract generation in progress

People’s Financial News, March 24 — Ganfeng Liyao (603087) announced on March 24 that recently, its wholly owned subsidiary Ganfeng Liyao Shandong Co., Ltd. received the “Notice of Approval for Clinical Trials” from the National Medical Products Administration for an additional indication for the investigational drug Bofangluetide Injection: “Moderate to severe obstructive sleep apnea in adult obese patients.” Bofangluetide Injection is an independently developed GLP-1 receptor agonist administered once every two weeks. Currently, Bofangluetide Injection is conducting Phase III clinical trials in China for indications including obesity/overweight management and type 2 diabetes.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.